FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (Post 2 of 2)

As promised and teased in yesterday’s blog post, we discuss other practical implications of and compliance concerns surrounding the ongoing shift in peptide policy below.

Supply Chain Complications

There is also a supply chain issue that sits upstream of any FDA regulatory authorization of their use in compounding.  Pursuant to Section 503A, these peptides must be manufactured at an FDA-registered drug establishment, and accompanied by a Certificate of Analysis.  Similarly, because they are likely sterile injectable products, they should be pharmaceutical-grade.

As the Alliance for Pharmacy Compounding’s (APC) CEO Scott Brunner put it:  Even if FDA acted tomorrow, pharmacies would still have to turn away those prescriptions because they couldn’t acquire the compliant API to prepare the drugs.  Compounding industry representatives have argued that the Agency must provide clearer forward-looking regulatory signals to incentivize the investment in pharmaceutical-grade supply chains.  Without that signal, manufacturers have little economic reason to build the infrastructure the market will need.

The Advertising Question

We bloggers believe one aspect of the potential peptide onslaught deserves mention here.  Even if peptides are finally placed in Category 1, and thus permissible for use in compounding, the advertising landscape will remain significantly constrained.  More specifically, pharmacies, practitioners, and online platforms may not promote compounded drugs using claims of safety or efficacy that otherwise imply FDA approval.  FDA has been unambiguous on this point in the GLP-1 context—issuing over eighty Warning Letters to telehealth companies for allegedly misleading marketing of compounded GLP-1 products in the twelve months ending March 2026—and there is every reason to expect the Agency to apply the same or similar framework to peptide marketing and promotion.  See, for example, FDA’s press release about the issuance of 30 Warning Letters to telehealth companies in early March 2026.  Companies positioning themselves for the anticipated booming peptide market should factor aggressive enforcement of promotional restrictions into their compliance planning from day one.

Industry Is Looking Ahead

APC has publicly supported authorizing production of certain peptides, while emphasizing the need for a pharmaceutical-grade and GMP-compliant API infrastructure first.  And stakeholders planning to weigh in have until July 9, 2026, to submit written comments to the docket (FDA–2025–N–6895); those interested in making oral presentations must notify FDA by June 30, 2026.

The Bottom Line

The peptide compounding policy environment is shifting—but deliberately and incrementally, not overnight—and likely too incrementally for those compounders ready to start dispensing peptides now.  The Category 2 removals and the ensuing July 2026 and early 2027 Pharmacy Compounding Advisory Committee (PCAC) meetings are seemingly meaningful procedural steps, and the political momentum behind this shift is real.  That said, compounders and industry participants should plan around a realistic timeline:  While there may be an interim period of enforcement discretion that may be announced by FDA around the time of the PCAC meetings, final rulemaking, if it proceeds smoothly, is still likely more than a year away; pharmaceutical-grade API supply chains need to be developed in parallel; and promotional restrictions will remain stringent regardless of what happens to the 503A list.

For companies with commercial interests in this space—whether compounding pharmacies, telehealth platforms, API manufacturers, or investors—this is a moment to evaluate the shifting regulatory landscape, and engage carefully and thoughtfully.  That may mean submitting comments to the docket, fostering supply chain and laboratory testing relationships, and/or designing marketing strategies with FDA’s promotional framework squarely in view.  The window for unregulated gray-market peptides may be closing, but the window for regulated compounded peptides is not yet fully open—and getting there likely will require navigating a more complex regulatory process than the current headlines or political/public fervor may suggest.

We will continue to monitor and report on developments in the peptide compounding space.